Allogeneic Cell Therapy Manufacturing Market Current Scenario with Future Trends Analysis to 2031

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " Global Allogeneic Cell Therapy Manufacturing Market Trends, Industry Competition Analysis, Revenue, and Forecast to 20301".

The Allogeneic Cell Therapy Manufacturing Market is expected to grow at a 15.0 % CAGR during the forecast period for 2023-2031.

Request for Free Sample Pages: https://www.insightaceanalytic.com/request-sample/1194

Allogeneic cell therapy products generate promising preclinical and clinical outcomes. Allogeneic cell therapies are created with healthy cells from unrelated donors, and they rely on a single source of cells to treat a significant number of patients. A patient receives healthy cells (stem cells) from a donor to replace their own damaged or obliterated cells.

During the forecast period, the demand for allogeneic cell therapy manufacturing is anticipated to be fueled by a number of factors, including the rising prevalence of chronic diseases such as cancer, diabetes, and cardiovascular disease, the increasing government funding for stem cell therapies, the growing elderly population, the development of healthcare infrastructure, technological advancements, and the growing public's awareness of the benefits of allogeneic cell therapies.

Moreover, Numerous pharmaceutical companies are developing allogeneic cell therapies for the treatment of chronic diseases. For instance, Adicet Bio, Inc., a biotechnology company developing allogeneic gamma delta T cell therapies for cancer and other diseases, initiated its First-in-Human Phase I clinical trial evaluating ADI-001 for the treatment of B cell non-Hodgkin's lymphoma (NHL) in March 2021. ADI-001 is an investigational first-in-class allogeneic gamma delta T cell therapy that expresses a chimeric antigen receptor (CAR) targeting CD20, produced to potentially increase selective tumor targeting and aid adaptive and innate anti-tumor immune response, as well as improve persistence for strong patient activity. In response to the rising demand for cost-effective and effective cell & gene therapies, contract research organizations (CROs) have expanded their bioassay services, thereby enhancing future market growth prospects.

Enquiry Before Buying: https://www.insightaceanalytic.com/enquiry-before-buying/1194

However, the high developmental investments and the immune rejection issues may inhibit the growth of the global allogeneic cell therapy manufacturing market in the upcoming years.

North America is projected to dominate this market over the forecast period (2019-2030), followed by Europe and Asia-Pacific, due to the growing R&D investments in cell therapy research, high prevalence of chronic diseases, and quick adoption of advanced technologies.

Major market players operating in the allogeneic cell therapy manufacturing market include Lonza Group, KBI Biopharma, Inc., Waisman Biomanufacturing, Cell, and Gene Therapy Catapult, Thermo Fisher Scientific, Inc., Merck KGaA, Catalent Inc., Oxford Biomedica Plc, Fujifilm Cellular Dynamics, Inc., Wuxi Apptec, Charles River Laboratories International, Inc., The Discovery Labs LLC, ABL, Inc., BioCentriq, Commercializing Living Therapies, and Other Prominent Player among others.

Get Specific Chapter/Information From The Report: https://www.insightaceanalytic.com/customisation/1194

Some significant developments in the market:
• In January 2022, Mesoblast Limited (Australi), a global leader in allogeneic cellular medicines for inflammatory diseases, presented 36-month follow-up results from thecPhase 3 trial of its allogeneic cell therapy rexlemestrocel-L (MPC-06-ID) in patients with CLBP (chronic low back pain) associated with DDD (degenerative disc disease). This trial showed a durable reduction in back pain lasting at least three years from a single intra-discal injection of rexlemestrocel-L+hyaluronic acid (HA) carrier.
• In November 2021, BONE THERAPEUTICS (Belgium), the cell therapy company, and Link Health Pharma Co., Ltd signed a non-binding term sheet for the global rights for ALLOB, allogeneic bone cell therapy of Bone Therapeutics'.
• In September 2021, Adaptimmune Therapeutics (UK) partnered with Roche Group (Genentech), to develop and commercialize allogeneic cell therapy for the treatment of multiple cancer indications.

Market Segments
Global Allogeneic Cell Therapy Manufacturing Market, by Product, 2019-2030 (Value US$ Mn)
• Induced pluripotent stem cells (iPSC)
• T-cells and Natural killer (NK) cells
• Human pluripotent stem cells (hPSCs)
• Mesenchymal stem cells (MSC)
• β-cells
• Neurons
• Immortalized and engineered cell lines
• Tissue engineered product
Global Allogeneic Cell Therapy Manufacturing Market, by By Scale of Operation, 2019-2030 (Value US$ Mn)
• Preclinical Scale Operations
• Clinical Scale Operations
• Commercial Scale Operations
Global Allogeneic Cell Therapy Manufacturing Market, by Region, 2019-2030 (Value US$ Mn)
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa
North America Allogeneic Cell Therapy Manufacturing Market, by Country, 2019-2030 (Value US$ Mn)
• U.S.
• Canada
Europe Allogeneic Cell Therapy Manufacturing Market, by Country, 2019-2030 (Value US$ Mn)
• Germany
• France
• Italy
• Spain
• Russia
• Rest of Europe
Asia Pacific Allogeneic Cell Therapy Manufacturing Market, by Country, 2019-2030 (Value US$ Mn)
• India
• China
• Japan
• South Korea
• Australia & New Zealand
Latin America Allogeneic Cell Therapy Manufacturing Market, by Country, 2019-2030 (Value US$ Mn)
• Brazil
• Mexico
• Rest of Latin America
Middle East & Africa Allogeneic Cell Therapy Manufacturing Market, by Country, 2019-2030 (Value US$ Mn)
• GCC Countries
• South Africa
• Rest of Middle East & Africa

Why should buy this market research report:
> To receive a detailed analysis of the prospects for the global allogeneic cell therapy manufacturing market
> To receive an industry overview and future trends and pipeline of the allogeneic cell therapy manufacturing market
> To analyze the allogeneic cell therapy manufacturing market drivers and challenges
> To get information on the allogeneic cell therapy manufacturing market size value (US$ Mn) forecast to 2030
> Significant investments, mergers & acquisitions in the allogeneic cell therapy manufacturing market industry

For More Information: https://www.insightaceanalytic.com/report/global-allogeneic-cell-therapy-manufacturing-market-/1194

Other Related Reports Published by InsightAce Analytic:
Global Immuno-Oncology Cell Therapy Market
Global Allogeneic Cell Therapies Market
Global CAR T-Cell Therapy For Multiple Myeloma Market
Global CD Targeted Cell Therapy Market

Corporate Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
loaction icon
Sales Office (U.S.) :
344 Grove St Unit #967 Jersey City, NJ 07302
email iconinfo@insightaceanalytic.com
call icon
North America:
+1 551 226 6109
Asia:
+91 79 72967118

Contact Us:
Dhanraj Zurange
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 551 226 6109
Asia: +91 79 72967118
Follow Us on LinkedIn @ bit.ly/2tBXsgS
Follow Us On Facebook @ bit.ly/2H9jnDZ

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

This release was published on openPR.